List of Letairis drug patents
Letairis is owned by Gilead.
Letairis contains Ambrisentan.
Letairis has a total of 3 drug patents out of which 0 drug patents have expired.
Letairis was authorised for market use on 15 June, 2007.
Letairis is available in tablet;oral dosage forms.
Letairis can be used as for the treatment of pulmonary hypertension (pah) in combination with tadalafil, for the treatment of pulmonary arterial hypertension (pah) in combination with tadalafil, wherein the weight ratio of ambrisentan to tadalafil is about 1:2 to about 1:3.
The generics of Letairis are possible to be released after 14 October, 2031.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9474752 | GILEAD | Method for treating a pulmonary hypertension condition |
Dec, 2027
(4 years from now) | |
| US8377933 | GILEAD | Method for treating a pulmonary hypertension condition |
Dec, 2027
(4 years from now) | |
| US9549926 | GILEAD | Compositions and methods of treating pulmonary hypertension |
Oct, 2031
(8 years from now) | |
Drugs and Companies using AMBRISENTAN ingredient
Market Authorisation Date: 15 June, 2007
Treatment: For the treatment of pulmonary hypertension (pah) in combination with tadalafil; For the treatment of pulmonary arterial hypertension (pah) in combination with tadalafil, wherein the weight ratio of ambrisentan to tadalafil is about 1:2 to about 1:3
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic